alaproclate
Sign in to saveAlaproclate (developmental code name GEA-654) is a drug that was being developed as an antidepressant by the Swedish pharmaceutical company Astra AB (now AstraZeneca) in the 1970s.
Research
114 papers- Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow.The Journal of pharmacology and experimental therapeutics · 1994
- Alaproclate effects on voltage-dependent K+ channels and NMDA receptors: studies in cultured rat hippocampal neurons and fibroblast cells transformed with Kv1.2 K+ channel cDNA.Neuropharmacology · 1994
- Alaproclate a novel antidepressant? A biochemical and clinical comparison with zimeldine.Acta psychiatrica Scandinavica · 1985
- Influence of alaproclate on antipyrine metabolite formation in man.European journal of clinical pharmacology · 1984
- Alaproclate--an open clinical study in depressive illness.Psychopharmacology · 1984
via PubMed
~1 min read
Encyclopedic overview
3 sectionsContents
- Synthesis
- See also
- References
Alaproclate (developmental code name GEA-654) is a drug that was being developed as an antidepressant by the Swedish pharmaceutical company Astra AB (now AstraZeneca) in the 1970s.
It acts as a selective serotonin reuptake inhibitor (SSRI), and along with zimelidine and indalpine, was one of the first of its kind. Development was discontinued due to the observation of liver complications in rodent studies. In addition to its SSRI properties, alaproclate has been found to act as a non-competitive NMDA receptor antagonist, but does not have discriminative stimulus properties similar to phencyclidine (PCP).
Excerpted from Wikipedia’s “alaproclate” article, available under the CC BY-SA 4.0 licence.